Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Chief Technology Officer | February 01, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date February 01, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2033-01-31 | Direct | 195,000 |
Reported balance
After 2023-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 195,000 · Balance 195,000 F1: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 2, 2023 17:21 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001854270-23-000020 · wf-form4_167537646100811.xml · derivative · entry 1 Lee Philip J · CIK 0001931711 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.